Randomized placebo-controlled trial of interferon alpha-2b plus ribavirin with and without lactoferrin for chronic hepatitis C.

Randomized placebo-controlled trial of interferon alpha-2b plus ribavirin with and without lactoferrin for chronic hepatitis C. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Randomized placebo-controlled trial of interferon alpha-2b plus ribavirin with and without lactoferrin for chronic hepatitis C. Abstract Text:

Yoko Ishibashi,Koichiro Takeda,Noriyuki Tsukidate,Hiroki Miyazaki,Koji Ohira,Hirotoshi Dosaka-Akita,Masaharu Nishimura,

Lactoferrin (LF), an iron-binding glycoprotein, exhibits several biological activities, including anti-viral activity and immunomodulatory functions. LF has been reported to inhibit hepatitis C virus (HCV) infection in cultured human hepatocytes and HCV viremia in low pretreatment HCV RNA titers of patients with chronic hepatitis C (CHC). However, the combination of interferon (IFN) alpha-2b plus ribavirin with LF for CHC has not been previously investigated. Thirty-six CHC patients, who were positive for HCV RNA with high serum levels of HCV RNA or who did not respond to or relapsed after interferon monotherapy, were randomly assigned to two groups: IFN alpha-2b and ribavirin plus LF for 24 weeks (18 patients), and IFN alpha-2b and ribavirin plus placebo (18 patients). Treatment was discontinued in three patients (17%) in the LF group and eight patients (44%) in the placebo group. For the 25 patients who finished the 24 weeks of treatment, virological sustained response was seen in 6 (40%) patients in the LF group and in 5 (50%) patients in the placebo group and there was no statistically significant difference between the two groups (p=0.7). Serum alanine aminotransferase concentrations remained normal throughout the follow-up period in nine patients (60%) in the LF group as compared with five patients (50%) in the placebo group (p=0.7). The proportion of patients with a virological or biochemical response at the end of the treatment period did not differ between the two groups. Furthermore, there were no statistically significant differences between the two groups in hemoglobin concentration, serum iron, ferritin, Th1/Th2 ratio or ribavirin concentration throughout the treatment and follow-up periods. In conclusion, we could not demonstrate that LF in combination with IFN alpha-2b and ribavirin increases the virological and biochemical response rate for CHC patients with high serum levels of HCV RNA or for CHC patients who do not response to or relapse after IFN monotherapy.

Randomized placebo-controlled trial of interferon alpha-2b plus ribavirin with and without lactoferrin for chronic hepatitis C. Publishing Authors By Initials

Y Ishibashi,K Takeda,N Tsukidate,H Miyazaki,K Ohira,H Dosaka-Akita,M Nishimura,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Randomized placebo-controlled trial of interferon alpha-2b plus ribavirin with and without lactoferrin for chronic hepatitis C. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Hepatology research : the official journal of the

VOLUME: 32

Page Numbers: 218-23

Journal Abbreviation:

ISSN: 1386-6346

DAY: 3

MONTH: 06

YEAR: 2005

Randomized placebo-controlled trial of interferon alpha-2b plus ribavirin with and without lactoferrin for chronic hepatitis C. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 9711801

Randomized placebo-controlled trial of interferon alpha-2b plus ribavirin with and without lactoferrin for chronic hepatitis C. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Randomized placebo-controlled trial of interferon alpha-2b plus ribavirin with and without lactoferrin for chronic hepatitis C. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Randomized placebo-controlled trial of interferon alpha-2b plus ribavirin with and without lactoferrin for chronic hepatitis C.

AFFILIATION: Department of Medical Oncology, Hokkaido University Graduate School of Medicine, N15W7, Kita-ku, Sapporo, Hokkaido 060-8638, Japan.

Country: Netherlands

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Hepatol Res

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Randomized placebo-controlled trial of interferon alpha-2b plus ribavirin with and without lactoferrin for chronic hepatitis C Related Publications

• A New Phenolic Glucoside, Curculigoside from Rhizomes of Curculigo orchioides.
• Action of ascorbic acid on a myosin molecule derived from carp.
• Alginate hydrogel linked with synthetic oligopeptide derived from BMP-2 allows ectopic osteoinduction in vivo.
• Analysis of N-glycan in serum glycoproteins from db/db mice and humans with type 2 diabetes.
• Arteriovenous malformation of the gallbladder: CT and angiographic findings.
• Combination tumor immunotherapy with radiotherapy and Th1 cell therapy against murine lung carcinoma.
• Continence care for older people.
• Dynamic memorization characteristics in neural networks with different neuronal dynamics.
• Evolution of life-history traits collapses competitive coexistence.
• Fluid-attenuated inversion-recovery SSFP imaging.
• Hemodynamics of ovarian veins: MR angiography in women with uterine leiomyomata.
• High glucose up-regulates lipopolysaccharide-stimulated inflammatory cytokine production via c-jun N-terminal kinase in the monocytic cell line THP-1.
• High peak inspiratory flow can aggravate ventilator-induced lung injury in rabbits.
• Influence of human CD8 on antigen recognition by T-cell receptor-transduced cells.
• Knockout of glutelin genes which form a tandem array with a high level of homology in rice by gamma irradiation.
• Management of urethral hemangiomas associated with Klippel-Trenaunay-Weber syndrome by endoscopic sclerotherapy.
• Multitensor tractography enables better depiction of motor pathways: initial clinical experience using diffusion-weighted MR imaging with standard b-value.
• PET measurement of FK506 concentration in a monkey model of stroke.
• Pharmacokinetics of telithromycin using bronchoscopic microsampling after single and multiple oral doses.
• Pitfall of percutaneous cardiopulmonary support for acute massive pulmonary embolism.
• Polarization of Healpha radiation due to anisotropy of fast-electron transport in ultraintense-laser-produced plasmas.
• Randomized placebo-controlled trial of interferon alpha-2b plus ribavirin with and without lactoferrin for chronic hepatitis C.
• Resilience, family adversity and well-being among Hawaiian and non-Hawaiian adolescents.
• Short term prediction of Ht value using BPNN during LCAP.
• Some characteristics of fluoride-induced cell death in rat thymocytes: cytotoxicity of sodium fluoride.
• Sternum fracture and haemorrhage after cardiopulmonary resuscitation.
• T cell immunotherapy.
• Three-dimensional bone-implant integration profiling using micro-computed tomography.
• Tumour necrosis factor alpha production by polymorphonuclear neutrophils treated with mouse anti-human CD19 monoclonal antibody.
• [Recent progress in paroxysmal nocturnal hemoglobinuria]